MedElevator
Войти в исследования Journal of cardiovascular echography · 2025
Hypertensive Response During Dobutamine Stress Echocardiography: Does it Indicate a Higher Risk of Developing Hypertension?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alimi Hedieh, Mirzaei Amirhossein, Farzaghi Maryam Soleimani, Rahimi Vafa Baradaran
Аннотация
BACKGROUND: One of the most common complications associated with dobutamine stress echocardiography (DSE) is abnormal blood pressure (BP) responses.
AIMS AND OBJECTIVES: The current investigation aimed to examine the blood pressure responses during DSE and its potential implications on cardiovascular outcomes.
METHODS: The study enrolled patients who lacked a history of hypertension and diabetes but demonstrated hypertensive response during DSE (n = 62). An equal number of patients who did not exhibit an increase in BP during the DSE were selected as the control group (n = 55). Throughout the 4-year clinical follow-up, we monitored the incidence of hypertension, myocardial infarction (MI), hospitalization due to heart disease, death, and stroke.
RESULTS: Among those who demonstrated a hypertensive response during DSE, baseline systolic BP (P = 0.002) and diastolic BP (P = 0.002) were notably higher compared to the nonhypertensive group. In addition, the hypertensive group received a significantly elevated dosage of dobutamine in comparison to the controls (P = 0.010). However, no statistically significant variances were observed between the two groups concerning death (P = 0.600), acute MI (P > 0.999), chronic hypertension (P = 0.063), diabetes mellitus (P = 0.513), and hospitalization (P = 0.472).
CONCLUSION: In light of our findings, hypertensive responses in patients undergoing DSE do not correlate with subsequent adverse outcomes. While our investigation did not identify a statistically significant difference in hypertension rates, it is essential to note that significance may be achieved with future research involving a larger sample size.
AIMS AND OBJECTIVES: The current investigation aimed to examine the blood pressure responses during DSE and its potential implications on cardiovascular outcomes.
METHODS: The study enrolled patients who lacked a history of hypertension and diabetes but demonstrated hypertensive response during DSE (n = 62). An equal number of patients who did not exhibit an increase in BP during the DSE were selected as the control group (n = 55). Throughout the 4-year clinical follow-up, we monitored the incidence of hypertension, myocardial infarction (MI), hospitalization due to heart disease, death, and stroke.
RESULTS: Among those who demonstrated a hypertensive response during DSE, baseline systolic BP (P = 0.002) and diastolic BP (P = 0.002) were notably higher compared to the nonhypertensive group. In addition, the hypertensive group received a significantly elevated dosage of dobutamine in comparison to the controls (P = 0.010). However, no statistically significant variances were observed between the two groups concerning death (P = 0.600), acute MI (P > 0.999), chronic hypertension (P = 0.063), diabetes mellitus (P = 0.513), and hospitalization (P = 0.472).
CONCLUSION: In light of our findings, hypertensive responses in patients undergoing DSE do not correlate with subsequent adverse outcomes. While our investigation did not identify a statistically significant difference in hypertension rates, it is essential to note that significance may be achieved with future research involving a larger sample size.